Top Pharmaceutical Companies (2,028)
Aadi Bioscience Inc. (Aadi) is a biopharmaceutical company focused on precision therapies for genetically-defined cancers. We strive to unleash the potential of mTOR inhibition by employing precision medicine & nanoparticle technology to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Our lead product has been FDA-approved for the treatment of adult patients with locally advanced unresectable or...
Wake Research is an integrated network of premier investigational sites working closely with and meeting the needs of the global biopharmaceutical, biotechnology, medical device, pharmaceutical industry, and clinical research organizations. Wake Research has its proprietary patient database of more than 2 million potential clinical trial participants—men and women, children and adults, across all ethnicities—for all kinds of adaptive and other...
Chemical Information Services provides product-based information services to the global chemical and pharmaceutical buyer communities.
The challenges facing healthcare are multifaceted. While others place bets on discovering new drugs or mass-producing old ones that work well enough, we are different. We believe that by improving the way therapies are formulated and used we can have the biggest impact. Our heritage as a trusted pharmacy for Swiss hospitals taught us that even small changes can make big...
Our primary focus is on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders.
Comprehensive Blood & Cancer Center (CBCC) is a specialized healthcare provider focused on cancer care, offering a comprehensive range of services including medical oncology, hematology, and radiation oncology. Additionally, CBCC operates a prominent Global Research department, acting as a leading clinical research organization that provides a broad spectrum of clinical trial services across various fields, including oncology, neuropsychiatry, and ophthalmology,...
AROG Pharmaceuticals, Inc. was formed to expedite and streamline the transition of early stage molecules into areas of unmet therapeutic needs. We are committed to scientifically validated drug development in collaboration with like-minded investigators and institutions.
Sustainability isn’t just about tackling climate change, it represents a growing conscience around our actions and the impact they have on people, animals and planet. The personal, professional and governmental move to sustainable practice is driven by a desire to change our impact on the world, but we can’t do this without knowing the certainty of our actions. Transparency...
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company.
Moleculin is a pharmaceutical company developing dermatological products to treat skin disorders.
Colorcon® is a world leader in the development, supply and technical support of formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical and nutritional industries. Our best-in-class products and technologies are complemented by our extensive formulation experience, application data and value-added services to support all phases of solid oral dose design, development and manufacture. Our focus...
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research and today our products are available in more than 100 countries. We are tirelessly dedicated to restoring brain health, so every person can be their best. The neuroscience market is on a growth trajectory. We see...
Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow's pipeline is led by SPI-62 in Phase 2 clinical development.
Kijimea is a German probiotic brand and healthcare company focused on researching, developing, and marketing scientifically validated probiotic preparations. Its work centers on the human microbiome, gut health, and digestive conditions such as irritable bowel syndrome. The company’s mission is to make probiotics a foundation for longer, healthier lives, serving more than 10 million customers across European and other international...
Hemostemix is a public clinical-stage company that develops and commercializes innovative blood-derived cell therapies for medical conditions that are not adequately addressed by current treatments. For more information, please visit www.hemostemix.com.
Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring...
Novogaia is a biotechnology company developing new medicines from fungi with artificial intelligence. Its platform combines machine learning, fungal genomics, and mass spectrometry/metabolomics to discover novel bioactive small molecules. The company targets applications in pharmaceuticals and agriculture, aiming to identify molecular matter that can modulate human biology and accelerate natural-product discovery for innovative therapeutic and agricultural uses through high-throughput screening...
Enrich is the leader in biotech and pharmaceutical portfolio management software, used in over half of the top 10 life sciences companies to value and manage portfolios of high risk, high investment assets. Our proprietary suite of tailored analytics and flexible on-demand visualizations are ideally suited for portfolio management.
We are building a synthetic alternative to cell therapies—a tunable, cell-free system that mimics regenerative signaling with precision across indications. Our first candidate targets Osteoarthritis.
KAHR is a clinical stage company developing novel immune-recruiting therapies that treat cancer at the source by unleashing the synergistic power of the body’s innate and adaptive immune responses. The company is leveraging its proprietary MIRP technology to promote better and safer therapeutic avenues by developing new immuno-recruitment drugs that unmask cancer camouflage mechanisms, while simultaneously recruiting a targeted immune response.
